

Table 1. Data for secondary clinical endpoint at each of the visits following baseline visit (T0). Data are shown for each of the group: dogs randomized to receive Q10 first, then placebo (Q10 first) and dogs randomized to receive placebo first, then Q10 (Placebo first).

Clinical Visit	T1		T2		T3	
Treatment Sequence	Q10 first	Placebo first	Q10 first	Placebo first	Q10 first	Placebo first
QoL	11.0 (10.0–11.0)	9.0 (8.0–10.0)	12.0 (11.0–13.0)	9.5 (8.0–11.8)	13.0 (12.0–13.0)	8.5 (8.0–12.3)
LVIDDN	2.1 (1.8–2.2)	1.8 (1.7–1.9)	2.1 (1.7–2.1)	1.9 (1.8–1.9)	2.0 (1.8–2.1)	1.8 (1.7–1.9)
FS (%)	40.0 (34.8–41.3)	38.0 (36.7–42.4)	39.8 (36.9–44.4)	39.4 (34.4–43.3)	39.5 (33.7)	38.6 (35.5–44.8)
EF (%)	76.9 (74.3–78.6)	78.2 (64.5–78.8)	75.1 (70.3–78.0)	80.1 (72.9–80.8)	75.8 (70.8–78.8)	77.4 (74.1–81.2)
LA/Ao	2.0 (1.9–2.3)	1.7 (1.6–2.0)	2.2 (1.6–2.6)	1.9 (1.6–2.1)	2.1 (1.8–2.2)	1.7 (1.7–2.0)
Platelet count (x106 platelets /mL)	276.0 (174–395)	254 (200.5–350.5)	274 (190–412)	278 (196.9–330.3)	265 (198–365)	261.5 (191.8–310.8)
Creatinine (μmol/L)	61.0 (56.0–68.0)	67.5 (63.3–71)	58.0 (55.0–77.0)	68 (60–78.5)	61.0 (58.0–75.0)	63 (60.3–70.8)
ALT (U/L)	41.0 (35.0–59.0)	43.5 (39.3–54.0)	41.0 (38.0–59.0)	43.5 (36.5–72.5)	41.0 (36.0–54.0)	41.0 (35.8–45.6)
NT-proBNP, ng/mL	1717.5 (1408.5–2660.8)	1307.0 (1118.8–1421.5)	1830.0 (1611.0–3860.0)	1343 (830.3–1703.0)	2202.0 (1604.0–4154.0)	1168.5 (878.3–1431.3)
CTnI (ng/mL)	0.052(0.039–0.074)	0.025(0.021–0.027)	0.053(0.036–0.065)	0.022(0.020–0.027)	0.052(0.035–0.096)	0.024(0.019–0.034)

Data are presented as median (interquartile range). FS, Fractional Shortening; EF, Ejection Fraction; LVIDDN, Left ventricular internal diameter in diastole normalized for body weight; LA/Ao, Left atrial to aortic root ratio; ALT, alanine aminotransferase; NT-proBNP; N terminal pro-B type natriuretic peptide; cTnI; cardiac troponin I; VHS, vertebral heart score.